

Psychopharmacological pattern in heart transplantation candidates

Roberto Sánchez¹, Eva Baillés², Josep M. Peri², Anna Bastidas², Félix Pérez-Villa³, Luis Pintor²

¹Department of Psychiatry. Institut de Neuropsiquiatria i Addiccions, Centre Emili Mira, Parc de Salut Mar, Barcelona.

²Department of Psychiatry. Institut de Neurociències. Hospital Clínic i Provincial de Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Universitat de Barcelona.

³Heart Transplantation Division. Department of Cardiology. Instituto Clínico del Tórax. Hospital Clínic i Provincial de Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Universitat de Barcelona.

e-mail address: 39639rsg@gmail.com

P.1.g.008

Introduction

Heart transplantation is a potentially life-saving procedure for people with terminal cardiac disease and it is considered the treatment of choice in cases of severe cardiac insufficiency refractory to medical or surgical treatment. The period between being listed for transplantation and receiving a heart is often particularly difficult and very stressful. Rates of psychiatric morbidity of around 50% have been found in these patients, mainly depressive and anxiety disorders. Psychopharmacological treatment is also very common, but no conclusive quantitative data are available. [1], [2]

Purpose

Describe the psychopharmacological treatment profile and make an approach to the most commonly used drugs, of patients in waiting period for heart transplantation. The secondary objective was to describe the cardiological and psychiatric features of these patients.

Methods

125 adult patients included consecutively in waiting list for HT between 2006 and 2012 (7 year period) were evaluated. All the patients were previously assessed by the HT medical team committee of Hospital Clínic of Barcelona and were suitable for being included in the program and meet general cardiology criteria for HT candidates (HT is indicated in those patients con severe heart failure, who underwent all other medical and surgical options, being the heart failure severely disabling with severe risk of death).

We analyzed the following variables: age, sex, years of disease progression, etiology of cardiopathy, axis I disorders applying structured clinical interview for DSM-IV and Hospital Anxiety and Depression Scale (HADS), and description of psychopharmacological pattern. We used descriptive statistics such means, averages and percentages.

Results

Demographic and clinical characteristics:

On average, the 125 patients of the sample were aged 55.47 ± 10.9 years. 98 were male (78.4%) and 27 female (21.6%). The mean of cardiac disease progression was 9.86 ± 8.2 years. The main etiologies of cardiopathy were ischemic cardiomyopathy (41.6%), non-ischemic cardiomyopathy (28.8%) and valvular cardiomyopathy (12%).


Psychopharmacological treatment profile:

A 31.2% of the sample (39 patients) was treated with psychopharmacological drugs at time of inclusion in waiting list, with this distribution: Benzodiazepines 16%; Selective Serotonin Reuptake Inhibitors 6.4%; Selective Serotonin Reuptake Inhibitors + Benzodiazepines 5.6%; Serotonin-Norepinephrine Reuptake Inhibitors 1.6% and other antidepressants 1.6%. No patient received treatment with antipsychotics or mood stabilizers. (Figure 1)

Psychiatric evaluation:

Axis I diagnoses were present in a 30.4% of patients of the sample, all of them included in depressive, anxiety, sleep and adjustment disorders. The mean score of HADS was 11.52 (SD = 6.3), with a mean score of 6.54 (SD = 3.8) in anxiety subscale and 4.97 (SD = 3.3) in depression subscale.

Fig. 1: Psychopharmacological treatment profile of the sample



Conclusions

About one third of patients in waiting list phase showed an axis I diagnosis and received psychopharmacological treatment, mainly anxiolytics and antidepressants. Selective Serotonin Reuptake Inhibitors was the most used group of antidepressants (used in 12% of the sample, 15 patients), may be due to positive profile of side effects and metabolic interactions in heart transplantation patients. The clinical characteristics of our sample are similar to the overall patient profile integrated in a heart transplant program. [1], [3]

References

- [1] Zipfel S, Schneider A, Jünger J, Herzog W. Anxiety, depressive symptoms and heart transplantation. In: Molinari E, Compare A, Parati G, editors. Clinical Psychology and Heart Disease. Italy: Springer, 2010; pp. 149-163.
- [2] Triffaux JM, Wauthy J, Bertrand J, Limet R, Albert A, Anseau M. Psychological evolution and assessment in patients undergoing orthotopic heart transplantation. Eur Psychiatry, 2001;16(3):180-5.
- [3] Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report - 2012. J Heart Lung Transplant, 2012;31(10):1052-64.

DISCLOSURE: There are no potential conflicts of interest.

